Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 OA Vaccine Revaccination and Persistence Study in Older Adults
NCT06534892Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Aug 2024
- Primary completion
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 17
01
Overview
A Phase 3 trial of GSK3003899A in respiratory syncytial virus infection (RSV), sponsored by GSK. Started Aug 2024; status: active, not recruiting.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06534892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06534892.